Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank69
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-50.94M
↑ 69% vs avg
Percentile
P69
Within normal range
Streak
3 yr
Consecutive growthExpanding
Average
$-163.29M
Historical baseline
PeriodValueYoY Change
TTM$-50.94M+26.1%
2024$-68.96M+64.5%
2023$-194.20M+29.3%
2022$-274.62M-18.8%
2021$-231.10M-24.7%
2020$-185.27M+23.2%
2019$-241.36M-11.9%
2018$-215.70M-100.2%
2017$-107.73M-70.9%
2016$-63.05M-